Merus MRUS Stock
Merus Price Chart
Merus MRUS Financial and Trading Overview
| Merus stock price | 37.39 USD |
| Previous Close | 26.5 USD |
| Open | 26.3 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 1000 |
| Day's Range | 26.24 - 26.97 USD |
| 52 Week Range | 12.03 - 30.81 USD |
| Volume | 429.13K USD |
| Avg. Volume | 467.73K USD |
| Market Cap | 1.33B USD |
| Beta (5Y Monthly) | 0.749647 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.35 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.7 USD |
MRUS Valuation Measures
| Enterprise Value | 992.44M USD |
| Trailing P/E | N/A |
| Forward P/E | -6.2459016 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 30.58373 |
| Price/Book (mrq) | 5.6817217 |
| Enterprise Value/Revenue | 22.852 |
| Enterprise Value/EBITDA | -5.901 |
Trading Information
Merus Stock Price History
| Beta (5Y Monthly) | 0.749647 |
| 52-Week Change | 34.15% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 30.81 USD |
| 52 Week Low | 12.03 USD |
| 50-Day Moving Average | 21.19 USD |
| 200-Day Moving Average | 18.93 USD |
MRUS Share Statistics
| Avg. Volume (3 month) | 467.73K USD |
| Avg. Daily Volume (10-Days) | 366.6K USD |
| Shares Outstanding | 49.8M |
| Float | 37.38M |
| Short Ratio | 12.59 |
| % Held by Insiders | 8.53% |
| % Held by Institutions | 79.67% |
| Shares Short | 4.94M |
| Short % of Float | 9.97% |
| Short % of Shares Outstanding | 9.93% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -390.78% |
| Gross Margin | -262.22% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.061% |
| Return on Equity (ttm) | -59.045% |
Income Statement
| Revenue (ttm) | 43.43M USD |
| Revenue Per Share (ttm) | 0.95 USD |
| Quarterly Revenue Growth (yoy) | 15.80% |
| Gross Profit (ttm) | -107838000 USD |
| EBITDA | -168195008 USD |
| Net Income Avi to Common (ttm) | -152042000 USD |
| Diluted EPS (ttm) | -3.64 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 241.24M USD |
| Total Cash Per Share (mrq) | 5.18 USD |
| Total Debt (mrq) | 13.18M USD |
| Total Debt/Equity (mrq) | 6.06 USD |
| Current Ratio (mrq) | 3.438 |
| Book Value Per Share (mrq) | 4.694 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -140244992 USD |
| Levered Free Cash Flow (ttm) | -73056128 USD |
Profile of Merus
| Country | United States |
| State | N/A |
| City | Utrecht |
| Address | Uppsalalaan 17 |
| ZIP | 3584 CT |
| Phone | 31 30 253 8800 |
| Website | https://www.merus.nl |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 164 |
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Q&A For Merus Stock
What is a current MRUS stock price?
Merus MRUS stock price today per share is 37.39 USD.
How to purchase Merus stock?
You can buy MRUS shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Merus?
The stock symbol or ticker of Merus is MRUS.
Which industry does the Merus company belong to?
The Merus industry is Biotechnology.
How many shares does Merus have in circulation?
The max supply of Merus shares is 69.09M.
What is Merus Price to Earnings Ratio (PE Ratio)?
Merus PE Ratio is now.
What was Merus earnings per share over the trailing 12 months (TTM)?
Merus EPS is -3.35 USD over the trailing 12 months.
Which sector does the Merus company belong to?
The Merus sector is Healthcare.
Merus MRUS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
10.08B USD — | 14784.03 USD — | 16292.28 USD — | — - | 10.08B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 1638.71 USD — |
-0.55
|
— — | 1547.55 USD — | 1705.12 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 3856.67 USD — |
-1.22
|
— — | 3700.88 USD — | 3966.57 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
- {{ link.label }} {{link}}